DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer

File Description SizeFormat
CLC13_369.pdf237.41 kBAdobe PDFView/Open

Title: Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer
Authors: Ikeda, Takaya / Nakamura, Yoichi / Yamaguchi, Hiroyuki / Tomonaga, Nanae / Doi, Seiji / Nakatomi, Katsumi / Iida, Tetsuya / Motoshima, Kohei / Mizoguchi, Kosuke / Nagayasu, Takeshi / Tsukamoto, Kazuhiro / Kohno, Shigeru
Issue Date: Sep-2012
Publisher: Elsevier
Citation: Clinical Lung Cancer, 13(5), pp.369-374; 2012
Abstract: Epidermal growth factor receptor (EGFR) mutations are predictive of response to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to detect EGFR mutations; however, it is not clear which is the most suitable for use in the clinic. In this study, we directly compare the clinical sensitivity and specificity of 3 PCR methods. We compared the 3 PCR methods (mutant-enriched PCR, PNA-LNA PCR, and PCR clamp) in patients with advanced NSCLC. A patient who showed sensitive mutations by at least 1 PCR method was treated with gefitinib. A patient who showed no sensitive mutations was treated with chemotherapy with cytotoxic agents. Fifty patients with advanced NSCLC previously untreated with EGFR-TKIs were enrolled in this trial. Seventeen patients were harboring EGFR mutations, 5 of whom showed discrepancies between the results of different PCR methods. All 5 patients responded to gefitinib. All patients harboring EGFR mutations received gefitinib treatment and 21 of 33 EGFR-mutation-negative patients received chemotherapy with cytotoxic agents. Median progression-free survival of the gefitinib group and the chemotherapy group were 8.2 and 5.9 months, respectively. We considered that all the discrepancies might be false negatives because the patients responded to gefitinib. To clarify the reason for the false negatives of each PCR method, and establish the clinical sensitivity and specificity of each PCR method, a large prospective clinical trial is warranted.
Keywords: EGFR mutations / Mutant-enriched PCR / Non-Small-cell lung cancer / PCR invader / Peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp
URI: http://hdl.handle.net/10069/30240
ISSN: 15257304
DOI: 10.1016/j.cllc.2012.01.008
Relational Links: http://hdl.handle.net/10069/32640
Rights: © 2012 Elsevier Inc. / NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 13, 5(2012)
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/30240

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace